Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase 3 1

Status

Completed 4Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 2Tumor-Agnostic 1Thoracic 1Other solid neoplasm 1Other hematologic neoplasm 1Dermatologic 1

Conditions

Pancreatic Adenocarcinoma 1Neoplasms, Unknown Primary 1Microsatellite Unstable Colorectal Cancer 1Melanoma 1Leukemia, Myelomonocytic, Chronic 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 302Carboplatin 155Nivolumab 154Cisplatin 139Cyclophosphamide 130Paclitaxel 127Magnetic Resonance Spectroscopy 98Specimen Handling 95Radiotherapy 90Gemcitabine 87Dexamethasone 83Biopsy 81Ipilimumab 78Docetaxel 75Doxorubicin 75Rituximab 69Etoposide 67atezolizumab 61durvalumab 60Lenalidomide 59Radiation 59Pemetrexed 58Taxes 57Bevacizumab 54Prednisone 54fludarabine 54olaparib 53Cytarabine 49Vincristine 49Fluorouracil 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Has results × cobimetinib × 1 year × Clear all
NCT03337698 2026-05-12

Morpheus Lung

Hoffmann-La Roche

Phase 1/2 Terminated
314 enrolled 31 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04409639 2026-04-24

CONCERTO

University of Utah

Phase 2 Active not recruiting
14 enrolled 20 charts
Other hematologic neoplasm

Leukemia, Myelomonocytic, Chronic

NCT03193190 2025-11-21

A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Hoffmann-La Roche

Phase 1/2 Completed
341 enrolled 28 charts
Gastrointestinal

Pancreatic Adenocarcinoma

NCT03498521 2025-11-19

CUPISCO

Hoffmann-La Roche

Phase 2 Completed
529 enrolled 16 charts
Tumor-Agnostic

Neoplasms, Unknown Primary

NCT02060188 2025-11-06

CheckMate142

Bristol-Myers Squibb

Phase 2 Completed
385 enrolled 17 charts 2 FDA
GastrointestinalOther solid neoplasm

Microsatellite Unstable Colorectal Cancer

NCT02908672 2025-07-20

A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

Hoffmann-La Roche

Phase 3 Completed
514 enrolled 25 charts 1 FDA
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡